The engineering and construction company is working with an outside consulting firm on a turnaround strategy. Those tend to be painful.
The company announced a stock offering to raise cash, but today's drop could've been much worse.
The business is raising cash through two offerings: one of debt and one of common stock.
Investors continue to sour on the solid oxide fuel cell developer.
The potential is significant. Unfortunately, so is the hype.
Throw in initial results from an important phase 2 clinical trial and investors might see four major pipeline events before the end of 2019.
It's not a household name, but has made a splash in tackling the biggest pain point in gene therapy: manufacturing.
These companies don't manufacture solar panels, but they do help customers generate electricity from the sun much more efficiently.
Investors continue to grapple with the uncertainty hanging over the company.
The company will receive a big windfall for a terminated collaboration. What happens next?
The company is issuing convertible debt to pad its balance sheet and fund late-stage clinical trials.
The generic drug distributor ended its fiscal year riding a surge of momentum -- and shares have doubled in the last month.
The United States could soon be adding 35,000 megawatts of new wind and solar capacity per year. Can this business capitalize on this opportunity?
The bioprocessing leader is having a bad day, but there doesn't appear to be any reason to panic.
Wall Street has soured on the company's prospects as it eyes a transition to commercial operations.
Regulators raised concerns with two of the company's drug candidates.
The lithium producer reported second-quarter 2019 operating results that showed the impact of significant headwinds.
The company's reliance on livestock animal products continues to weigh on operating results, so it announced a huge transaction to address that weakness.
Investors continued to back away from the troubled generic-drug company as lawsuits from the opioid crisis began to conclude.
The animal health leader reported solid second-quarter 2019 operating results, but headwinds are brewing.